108.29
0.81%
+0.8593
Jazz Pharmaceuticals plc stock is currently priced at $108.29, with a 24-hour trading volume of 33,477.
It has seen a +0.81% increased in the last 24 hours and a -8.16% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $107.9 pivot point. If it approaches the $108.6 resistance level, significant changes may occur.
Previous Close:
$107.43
Open:
$107
24h Volume:
33,477
Market Cap:
$6.70B
Revenue:
$3.83B
Net Income/Loss:
$414.83M
P/E Ratio:
-68.97
EPS:
-1.57
Net Cash Flow:
$1.05B
1W Performance:
-1.49%
1M Performance:
-8.16%
6M Performance:
-15.96%
1Y Performance:
-21.48%
Jazz Pharmaceuticals plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals plc
Sector
Industry
Phone
353 1 634 7800
Address
Waterloo Exchange, Fifth Floor Waterloo Road, Dublin
Jazz Pharmaceuticals plc Stock (JAZZ) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-03-24 | Initiated | Robert W. Baird | Outperform |
Nov-27-23 | Downgrade | UBS | Buy → Neutral |
Sep-29-23 | Initiated | Raymond James | Mkt Perform |
Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
Jun-14-22 | Initiated | UBS | Buy |
Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
Nov-19-21 | Resumed | Goldman | Buy |
Oct-07-21 | Resumed | Jefferies | Buy |
Oct-05-21 | Initiated | Citigroup | Buy |
Sep-23-21 | Initiated | Needham | Buy |
May-19-21 | Resumed | JP Morgan | Overweight |
Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-16-20 | Initiated | UBS | Buy |
Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
Sep-14-20 | Resumed | JP Morgan | Overweight |
Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
Apr-06-20 | Initiated | Jefferies | Buy |
Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
Jan-08-20 | Initiated | Goldman | Neutral |
Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
Jun-11-19 | Initiated | Barclays | Overweight |
Mar-20-19 | Initiated | SunTrust | Buy |
Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
Nov-08-18 | Reiterated | B. Riley FBR | Buy |
Aug-08-18 | Reiterated | Stifel | Buy |
Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals plc Stock (JAZZ) Latest News
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks Investment Research
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks Investment Research
3 No-Brainer Stocks to Buy With $300 Right Now
The Motley Fool
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Zacks Investment Research
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
Benzinga
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
Zacks Investment Research
Jazz Pharmaceuticals plc Stock (JAZZ) Financials Data
Jazz Pharmaceuticals plc (JAZZ) Revenue 2024
JAZZ reported a revenue (TTM) of $3.83 billion for the quarter ending December 31, 2023, a +4.78% rise year-over-year.
Jazz Pharmaceuticals plc (JAZZ) Net Income 2024
JAZZ net income (TTM) was $414.83 million for the quarter ending December 31, 2023, a +285.14% increase year-over-year.
Jazz Pharmaceuticals plc (JAZZ) Cash Flow 2024
JAZZ recorded a free cash flow (TTM) of $1.05 billion for the quarter ending December 31, 2023, a +35.57% increase year-over-year.
Jazz Pharmaceuticals plc (JAZZ) Earnings per Share 2024
JAZZ earnings per share (TTM) was $6.12 for the quarter ending December 31, 2023, a +272.39% growth year-over-year.
Jazz Pharmaceuticals plc Stock (JAZZ) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Carr Patricia | SVP, Chief Accounting Officer |
Mar 07 '24 |
Sale |
116.98 |
1,768 |
206,821 |
6,596 |
Carr Patricia | SVP, Chief Accounting Officer |
Mar 06 '24 |
Sale |
119.64 |
1,936 |
231,628 |
8,364 |
Johnson Philip L | EVP & Chief Financial Officer |
Mar 01 '24 |
Buy |
119.65 |
12,000 |
1,435,800 |
27,932 |
Cook Jennifer E. | Director |
Dec 04 '23 |
Sale |
119.27 |
417 |
49,736 |
6,888 |
Smith Mark Douglas | Director |
Dec 04 '23 |
Sale |
119.27 |
417 |
49,736 |
6,888 |
Patil Neena M | EVP & Chief Legal Officer |
Sep 01 '23 |
Sale |
144.25 |
1,500 |
216,375 |
29,186 |
Carr Patricia | SVP, Chief Accounting Officer |
Aug 29 '23 |
Sale |
143.47 |
142 |
20,373 |
5,986 |
Patil Neena M | EVP & Chief Legal Officer |
Aug 15 '23 |
Sale |
139.59 |
750 |
104,695 |
30,686 |
McSharry Heather Ann | Director |
Aug 14 '23 |
Sale |
138.16 |
1,344 |
185,685 |
16,778 |
Sohn Catherine A. | Director |
Aug 14 '23 |
Sale |
138.16 |
1,241 |
171,455 |
14,868 |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Cap:
|
Volume (24h):